drugset / Trial / NCT02461888
Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
Phase 2
Completed
112 enrolled
University of Leeds
Millennium Pharmaceuticals, Inc. · collabMyeloma UK · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates a new treatment combination of ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory multiple myeloma. Participants will either receive ixazomib with cyclophosphamide and dexamethasone or cyclophosphamide and dexamethasone alone.
Timeline
- Start
- 2015-12
- Primary completion
- 2022-04
- Completion
- 2025-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 500 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |